Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAM: Adjuvant Apalutamide in High-Risk Prostate Cancer
NCT04295447Phase 2Active, not recruiting
- Sponsor
- Universität Münster
- Start
- Dec 2020
- Primary completion
- Nov 2028
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of apalutamide in prostate cancer (PCa), sponsored by Universität Münster. Started Dec 2020; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04295447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295447.